Lords Mark bets big on AI-driven dialysis tech, buys 85% stake in Renalyx Health

Renalyx will continue operating as an independent unit within the group

Enlivex reports promising six-month data for Allocetra in knee osteoarthritis

Call it a ray of hope for those enduring the pain of knee osteoarthritis -- the most common form of arthritis, affecting over 300 million people worldwide

EU greenlights Dupixent for chronic urticaria, offering new hope to patients

It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria

Valneva Phase 2 data for Lyme disease vaccine candidate shows striking immune response

Pfizer and Valneva have been collaborating on VLA15’s development and commercialization since April 2020

Otsuka files FDA application for first-in-class ADHD drug

Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor

Novo Nordisk’s new diabetes combo drug delivers big wins in mid-stage trial

The trial tested six injectable doses and three oral doses over as long as 36 weeks

Novartis scores FDA nod for game-changing SMA treatment

Itvisma is a one-time, fixed-dose therapy designed to tackle the genetic root cause of SMA

EU clears Bristol Myers Squibb’s CAR-T therapy Breyanzi for tough-to-treat Lymphoma

The European Commission’s green light marks Breyanzi’s fourth indication in Europe and extends access to patients across all EU and EEA countries

Eli Lilly to unveil major breast cancer data at SABCS 2025

Data show adjuvant Verzenio plus endocrine therapy extends overall survival and sustains long-term improvements in invasive disease-free survival

Merck KGaA’s Cladribine capsules gain FDA fast track for rare neuromuscular disorder